The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
Dr. Bart L Scott on Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
By The Cancer News Team
Summary of Dr. Bart L. Scott’s presentation on first-line treatment strategies for newly diagnosed acute myeloid leukemia, highlighting azacitidine–venetoclax, the Paradigm trial, and patient-centered decision-making.
Dr. Bart L Scott on Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
By The Cancer News Team
Summary of Dr. Bart L. Scott’s presentation on first-line treatment strategies for newly diagnosed acute myeloid leukemia, highlighting azacitidine–venetoclax, the Paradigm trial, and patient-centered decision-making.
Dr. Bart L Scott on Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
By The Cancer News Team
Summary of Dr. Bart L. Scott’s presentation on first-line treatment strategies for newly diagnosed acute myeloid leukemia, highlighting azacitidine–venetoclax, the Paradigm trial, and patient-centered decision-making.
How Medical Oncologists Select Targeted Therapies for Breast Cancer ESR1 and Pancreatic MTAP Mutations
By The Cancer News Team
Expert tumor board discussion from the Precision Oncology Summit on ESR1-mutant breast cancer and MTAP-deleted pancreatic cancer, highlighting real-world cases, oral SERDs, PRMT5 inhibitors, and biomarker-driven treatment decisions.
How Medical Oncologists Select Targeted Therapies for Breast Cancer ESR1 and Pancreatic MTAP Mutations
By The Cancer News Team
Expert tumor board discussion from the Precision Oncology Summit on ESR1-mutant breast cancer and MTAP-deleted pancreatic cancer, highlighting real-world cases, oral SERDs, PRMT5 inhibitors, and biomarker-driven treatment decisions.
How Medical Oncologists Select Targeted Therapies for Breast Cancer ESR1 and Pancreatic MTAP Mutations
By The Cancer News Team
Expert tumor board discussion from the Precision Oncology Summit on ESR1-mutant breast cancer and MTAP-deleted pancreatic cancer, highlighting real-world cases, oral SERDs, PRMT5 inhibitors, and biomarker-driven treatment decisions.
New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia
By Dr. Akriti Jain
A leukemia specialist discusses new insights from a multicenter U.S. study on blast phase chronic myeloid leukemia, highlighting treatment patterns, outcomes, and the critical role of TKIs and transplantation.
New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia
By Dr. Akriti Jain
A leukemia specialist discusses new insights from a multicenter U.S. study on blast phase chronic myeloid leukemia, highlighting treatment patterns, outcomes, and the critical role of TKIs and transplantation.
New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia
By Dr. Akriti Jain
A leukemia specialist discusses new insights from a multicenter U.S. study on blast phase chronic myeloid leukemia, highlighting treatment patterns, outcomes, and the critical role of TKIs and transplantation.
Artificial Intelligence Transforming Precision Medicine: From Genetic Discovery to Patient Monitoring
By The Cancer News Team
Artificial intelligence is transforming precision medicine by enabling genetic discovery, continuous patient monitoring, personalized diabetes care, and advanced medical imaging to improve cancer outcomes.
Artificial Intelligence Transforming Precision Medicine: From Genetic Discovery to Patient Monitoring
By The Cancer News Team
Artificial intelligence is transforming precision medicine by enabling genetic discovery, continuous patient monitoring, personalized diabetes care, and advanced medical imaging to improve cancer outcomes.
Artificial Intelligence Transforming Precision Medicine: From Genetic Discovery to Patient Monitoring
By The Cancer News Team
Artificial intelligence is transforming precision medicine by enabling genetic discovery, continuous patient monitoring, personalized diabetes care, and advanced medical imaging to improve cancer outcomes.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
ASH 2025 Highlights: Top Hematology Research Abstracts, Selected by Field Experts
By The Cancer News Team
A curated expert review of the most impactful leukemia and myeloproliferative neoplasm (MPN) research abstracts presented at the 2025 American Society of Hematology (ASH) Annual Meeting.
ASH 2025 Highlights: Top Hematology Research Abstracts, Selected by Field Experts
By The Cancer News Team
A curated expert review of the most impactful leukemia and myeloproliferative neoplasm (MPN) research abstracts presented at the 2025 American Society of Hematology (ASH) Annual Meeting.
ASH 2025 Highlights: Top Hematology Research Abstracts, Selected by Field Experts
By The Cancer News Team
A curated expert review of the most impactful leukemia and myeloproliferative neoplasm (MPN) research abstracts presented at the 2025 American Society of Hematology (ASH) Annual Meeting.